{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T23:09:01Z","timestamp":1648595341385},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T00:00:00Z","timestamp":1567209600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T00:00:00Z","timestamp":1567209600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s11886-019-1199-4","type":"journal-article","created":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T11:12:33Z","timestamp":1567249953000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Can Direct Oral Anticoagulants Be Used for Stroke Prevention Among Patients with Valvular Atrial Fibrillation?"],"prefix":"10.1007","volume":"21","author":[{"given":"Sarah L.","family":"Anderson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel C.","family":"Marrs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,31]]},"reference":[{"key":"1199_CR1","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","volume":"139","author":"EJ Benjamin","year":"2019","unstructured":"Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics \u2013 2019 update: a report from the American Heart Association. Circulation. 2019;139:e56\u2013e528. \n                      https:\/\/doi.org\/10.1161\/CIR.0000000000000659\n                      \n                    .","journal-title":"Circulation"},{"key":"1199_CR2","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1161\/01.CIR.0000140263.20897.42","volume":"110","author":"DM Lloyd-Jones","year":"2004","unstructured":"Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110:1042\u20136. \n                      https:\/\/doi.org\/10.1161\/01.CIR.0000140263.20897.42\n                      \n                    .","journal-title":"Circulation"},{"key":"1199_CR3","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1056\/NEJM198204293061703","volume":"306","author":"WB Kannel","year":"1982","unstructured":"Kannel WB, Abbott RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: the Framingham Study. N Engl J Med. 1982;306:1018\u201322. \n                      https:\/\/doi.org\/10.1056\/NEJM198204293061703\n                      \n                    .","journal-title":"N Engl J Med"},{"key":"1199_CR4","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1161\/01.CIR.98.10.946","volume":"98","author":"EJ Benjamin","year":"1998","unstructured":"Benjamin EJ, Wolf PA, D\u2019Agostino RB, Sibershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946\u201352. \n                      https:\/\/doi.org\/10.1161\/01.CIR.98.10.946\n                      \n                    .","journal-title":"Circulation"},{"key":"1199_CR5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S0735-1097(00)01107-4","volume":"37","author":"SS Chugh","year":"2001","unstructured":"Chugh SS, Blackshear JL, Shen WK, Hammill SC, Gersh BJ. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol. 2001;37:371. \n                      https:\/\/doi.org\/10.1016\/S0735-1097(00)01107-4\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"key":"1199_CR6","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1161\/CIRCULATIONAHA.114.008201","volume":"129","author":"NJ Patel","year":"2014","unstructured":"Patel NJ, Deshmukh A, Pant S, et al. Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning. Circulation. 2014;129:2371\u20139. \n                      https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.008201\n                      \n                    .","journal-title":"Circulation"},{"issue":"7","key":"1199_CR7","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1016\/j.hrthm.2019.01.024","volume":"16","author":"CT January","year":"2019","unstructured":"\u2022\u2022 January CT, Wann LS, Calkins H, et al. 2019 AHA\/ACC\/HRS focused update of the 2015 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2019;16(7. Updated guidelines that more clearly define valvular vs. non-valvular atrial fibrillation and provides recommendations based on the latest evidence):e66\u201393. \n                      https:\/\/doi.org\/10.1016\/j.hrthm.2019.01.024\n                      \n                    .","journal-title":"Heart Rhythm"},{"key":"1199_CR8","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1093\/eurheartj\/ehu352","volume":"35","author":"R De Caterina","year":"2014","unstructured":"De Caterina R, Camm AJ. What is \u201cvalvular\u201d atrial fibrillation? A reappraisal. Eur Heart J. 2014;35:3328\u201335. \n                      https:\/\/doi.org\/10.1093\/eurheartj\/ehu352\n                      \n                    .","journal-title":"Eur Heart J"},{"key":"1199_CR9","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin III JP, Fleisher LA, Jneid H, Mack MJ, McLeod CJ, O\u2019Gara PT, Rigolin VH, Sundt III TM, Thompson A 2017 ACC\/AHA focused update of the 2014 AHA\/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017;70(2):252\u2013289. \n                      https:\/\/doi.org\/10.1161\/CIR.0000000000000503\n                      \n                    . 9. Updated guidelines that more clearly define valvular vs. non-valvular atrial fibrillation and provides recommendations based on the latest evidence.","DOI":"10.1161\/CIR.0000000000000503"},{"key":"1199_CR10","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMc1112500","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981\u201392. \n                      https:\/\/doi.org\/10.1056\/NEJMc1112500\n                      \n                    .","journal-title":"N Engl J Med"},{"key":"1199_CR11","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139\u201351. \n                      https:\/\/doi.org\/10.1056\/NEJMoa0905561\n                      \n                    .","journal-title":"N Engl J Med"},{"issue":"22","key":"1199_CR12","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"Robert P. Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, \u0160pinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM, ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093\u20132104. DOI: \n                      https:\/\/doi.org\/10.1056\/NEJMoa1310907\n                      \n                    .","journal-title":"New England Journal of Medicine"},{"key":"1199_CR13","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMc1112233","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883\u201391. \n                      https:\/\/doi.org\/10.1056\/NEJMc1112233\n                      \n                    .","journal-title":"N Engl J Med"},{"key":"1199_CR14","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.014807","volume":"132","author":"A Avezum","year":"2015","unstructured":"Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, et al. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. Circulation. 2015;132:624\u201332. \n                      https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.014807\n                      \n                    .","journal-title":"Circulation"},{"issue":"15","key":"1199_CR15","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1136\/heartjnl-2017-312272","volume":"104","author":"D Vinereanu","year":"2018","unstructured":"Vinereanu D, Wang A, Mulder H, Lopes RD, Jansky P, Lewis BS, et al. Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease. Heart. 2018;104(15):1292\u20139. \n                      https:\/\/doi.org\/10.1136\/heartjnl-2017-312272\n                      \n                    .","journal-title":"Heart"},{"issue":"8","key":"1199_CR16","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1161\/CIRCULATIONAHA.115.020950","volume":"134","author":"MD Ezekowitz","year":"2016","unstructured":"Ezekowitz MD, Nagarakanti R, Noack H, Brueckmann M, Litherland C, Jacobs M, et al. Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY trial (randomized evaluation of long-term anticoagulant therapy). Circulation. 2016;134(8):589\u201398. \n                      https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.020950\n                      \n                    .","journal-title":"Circulation"},{"issue":"11","key":"1199_CR17","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.jacc.2016.12.031","volume":"69","author":"R De Caterina","year":"2017","unstructured":"De Caterina R, Renda G, Carnicelli AP, et al. Valvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. J Am Coll Cardiol. 2017;69(11):1372\u201382. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2016.12.031\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"47","key":"1199_CR18","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1093\/eurheartj\/ehu305","volume":"35","author":"G Breithardt","year":"2014","unstructured":"Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Stevens SR, et al. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J. 2014;35(47):3377\u201335. \n                      https:\/\/doi.org\/10.1093\/eurheartj\/ehu305\n                      \n                    .","journal-title":"Eur Heart J"},{"key":"1199_CR19","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/heartjnl-2015-308120","volume":"102","author":"G Breithardt","year":"2016","unstructured":"Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Lokhnygina Y, et al. Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. Heart. 2016;102:1036\u201343. \n                      https:\/\/doi.org\/10.1136\/heartjnl-2015-308120\n                      \n                    .","journal-title":"Heart"},{"key":"1199_CR20","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.jacc.2016.12.038","volume":"69","author":"G Renda","year":"2017","unstructured":"Renda G, Ricci F, Giugliano RP, De Caterina R. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease. J Am Coll Cardiol. 2017;69:1363\u201371. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2016.12.038\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"key":"1199_CR21","doi-asserted-by":"publisher","first-page":"e005835","DOI":"10.1161\/JAHA.117.005835","volume":"6","author":"KL Pan","year":"2017","unstructured":"Pan KL, Singer DE, Ovbiagele B, Wu YL, Ahmed MA, Lee M. Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis. J Am Heart Assoc. 2017;6:e005835. \n                      https:\/\/doi.org\/10.1161\/JAHA.117.005835\n                      \n                    .","journal-title":"J Am Heart Assoc"},{"key":"1199_CR22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/ehjcvp\/pvx028","volume":"4","author":"D Caldeira","year":"2018","unstructured":"Caldeira D, David C, Costa J, Ferreira JJ, Pinto FJ. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2018;4:111\u20138. \n                      https:\/\/doi.org\/10.1093\/ehjcvp\/pvx028\n                      \n                    .","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"1199_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40268-016-0124-1","volume":"16","author":"AR Duraes","year":"2016","unstructured":"Duraes AR, de Souza RP, de Almeida NB, et al. Dabigatran versus warfarin after bioprosthesis valve replacement for the management of atrial fibrillation postoperatively: DAWA Pilot Study. Drugs RD. 2016;16:149\u201354. \n                      https:\/\/doi.org\/10.1007\/s40268-016-0124-1\n                      \n                    .","journal-title":"Drugs RD"},{"key":"1199_CR24","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jacc.2018.12.047","volume":"73","author":"JY Kim","year":"2018","unstructured":"Kim JY, Kim SH, Myong JP, et al. Outcomes of direct oral anticoagulants in patients with mitral stenosis. J Am Coll Cardiol. 2018;73:1123\u201331. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2018.12.047\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"key":"1199_CR25","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.jtcvs.2011.02.011","volume":"141","author":"SH McKellar","year":"2011","unstructured":"McKellar SH, Abel S, Camp CL, Suri RM, Ereth MH, Schaff HV. Effectiveness of dabigatran etexilate for thromboprophylaxis of mechanical heart valves. J Thorac Cardiovasc Surg. 2011;141:1410\u20136. \n                      https:\/\/doi.org\/10.1016\/j.jtcvs.2011.02.011\n                      \n                    .","journal-title":"J Thorac Cardiovasc Surg"},{"key":"1199_CR26","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1161\/ATVBAHA.116.308649","volume":"37","author":"PA Lester","year":"2017","unstructured":"Lester PA, Coleman DM, Diaz JA, Jackson TO, Hawley AE, Mathues AR, et al. Apixaban versus warfarin for mechanical heart valve thromboprophylaxis in a swine aortic heterotopic valve model. Arterioscler Thromb Vasc Biol. 2017;37:942\u20138. \n                      https:\/\/doi.org\/10.1161\/ATVBAHA.116.308649\n                      \n                    .","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"1199_CR27","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/jth.12500","volume":"12","author":"J. W. Eikelboom","year":"2014","unstructured":"\u2022 Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369:1206\u20131214. doi: \n                      https:\/\/doi.org\/10.1111\/jth.12500\n                      \n                    . 27. This is the only DOAC clinical trial in patients with mechanical heart valves.","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"1199_CR28","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/clc.23178","volume":"42","author":"PO Guimaraes","year":"2019","unstructured":"Guimaraes PO, Pokorney SD, Lopes RD, et al. Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: insights from the ARISTOTLE trial. Clin Cardiol. 2019;42:568\u201371. \n                      https:\/\/doi.org\/10.1002\/clc.23178\n                      \n                    .","journal-title":"Clin Cardiol"},{"key":"1199_CR29","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1055\/s-0038-1676816","volume":"119","author":"KR An","year":"2019","unstructured":"An KR, Belley-Cote EP, Um KJ, Gupta S, McClure G, Jaffer I, et al. Antiplatelet therapy versus anticoagulation after surgical bioprosthetic aortic valve replacement: a systematic review and meta-analysis. Thromb Haemost. 2019;119:328\u201339. \n                      https:\/\/doi.org\/10.1055\/s-0038-1676816\n                      \n                    .","journal-title":"Thromb Haemost"},{"key":"1199_CR30","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/j.athoracsur.2018.10.016","volume":"107","author":"JN Papak","year":"2019","unstructured":"Papak JN, Chiovaro JC, Noelck N, Healy LD, Freeman M, Quin JA, et al. Antithrombotic strategies after bioprosthetic aortic valve replacement: a systematic review. Ann Thorac Surg. 2019;107:1571\u201381. \n                      https:\/\/doi.org\/10.1016\/j.athoracsur.2018.10.016\n                      \n                    .","journal-title":"Ann Thorac Surg"},{"key":"1199_CR31","doi-asserted-by":"publisher","first-page":"110","DOI":"10.2174\/1874192401610010110","volume":"10","author":"S Ahmad","year":"2016","unstructured":"Ahmad S, Wilt H. Stroke prevention in atrial fibrillation and valvular heart disease. Open Cardiovasc Med J. 2016;10:110\u20136. \n                      https:\/\/doi.org\/10.2174\/1874192401610010110\n                      \n                    .","journal-title":"Open Cardiovasc Med J"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-019-1199-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11886-019-1199-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-019-1199-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,29]],"date-time":"2020-08-29T23:30:15Z","timestamp":1598743815000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11886-019-1199-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,31]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["1199"],"URL":"https:\/\/doi.org\/10.1007\/s11886-019-1199-4","relation":{},"ISSN":["1523-3782","1534-3170"],"issn-type":[{"value":"1523-3782","type":"print"},{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,31]]},"assertion":[{"value":"31 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Sarah L. Anderson and Joel C. Marrs declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"118"}}